<DOC>
	<DOCNO>NCT01532570</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics TA-650 patient Behcet 's disease ( BD ) special lesion administration TA-650 dosage 5 mg/kg week 0 , 2 , 6 , every 8 week week 14 week 46 .</brief_summary>
	<brief_title>Clinical Study TA-650 Patients With Behcet 's Disease ( BD ) With Special Lesions</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>Patients diagnose complete incomplete type Behcet 's disease accord `` The criterion diagnosis Behcet 's disease , Ministry Health , Labour Welfare Japan ( partially revise 2010 ) '' Patients special lesion despite received conventional treatment special lesion , patient receive conventional treatment due intolerability . Patients clinical symptom associate special lesion . Patients intestinal , neuro , vascular Behcet 's disease differential diagnosis Behcet 's disease conditionsï¼Ž Patients receive treatment infliximab within 1 year enrollment another purpose treat special lesion ; patient whose previous treatment infliximab discontinue due adverse event . Patients participate another clinical study receive study drug within 12 week give acquirement .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Behcet 's disease</keyword>
	<keyword>intestinal Behcet 's disease</keyword>
	<keyword>neuro-Behcet 's disease</keyword>
	<keyword>vascular Behcet 's disease</keyword>
</DOC>